crudeoil24
3 years ago
BTX > "company said it has established a research and development center in Cambridge, Mass., to pursue its mRNA-based gene editing and cellular therapies.
The company said it has co-located with Factor Bioscience Limited and Novellus Therapeutics Limited, from which Brooklyn has acquired an exclusive worldwide license to develop and commercialize certain cell-based therapies to treat cancer and rare blood disorders, including sickle cell disease, based on the patented technology and know-how of Factor and Novellus.
"We believe co-locating with Factor and Novellus will promote our capability to leverage our collaboration and further our objectives in developing a diversified portfolio of new, advanced therapeutics," said Howard J. Federoff, Brooklyn's chief executive and president.
Brooklyn's recently licensed platform from Factor and Novellus includes three novel technologies that the company expects to pursue at its new R&D location.
The first is a highly efficient mRNA cell reprogramming method. The second is a mRNA-based gene editing technology which can be applied to both allogeneic and autologous cells and which eliminates potential for off-target effects. The third is a proprietary tunable nanolipid delivery system that provides efficient non-viral vector-based delivery of mRNA ex vivo and in vivo to skin, brain, eye and lung tissue."
Write to Chris Wack at chris.wack@wsj.com
conix
3 years ago
Careful. Got out at the open--not because I do not think this cannot become another GME play, just that at some point ....
Is Brooklyn ImmunoTherapeutics the next GameStop?
May 01, 2021 4:00 PM ETBrooklyn ImmunoTherapeutics, Inc. (BTX)
By: Jonathan M Block, SA News Editor
One of the best performing stocks in April was Brooklyn ImmunoTherapuetics (NYSEMKT:BTX), which only began trading in late March.
Shares have risen more than 1200% in the last month.
Brooklyn was formed through a reverse merger with the trivia apps company NTN Buzztime.
In April, Brooklyn's biggest announcement was its acquisition of an exclusive license for mRNA gene editing and cell therapies technology.
However, given the sudden rise in share price on little news or other catalysts, some are saying that Brooklyn is the target of a short squeeze play.
Users on the Wall Street Bets Reddit channel, the same group behind GameStop's spectacular rise earlier this year, have said for some time they have wanted to target biotech stocks as potential short squeeze plays.
Joshua Rodriguez of CNA Finance noted last month that before it became Brooklyn Immunotherapeutics, NTN Buzztime was heavily shorted and after the merger, the public float was only 1.12M shares.
The company's sole asset, IRX-2, is in phase 2b for squamous cell cancer of the head and neck and results are expected by the end of 1H 2021.